Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size.

Laidlaw TM, Prussin C, Panettieri RA, Lee S, Ferguson BJ, Adappa ND, Lane AP, Palumbo ML, Sullivan M, Archibald D, Dworetzky SI, Hebrank GT, Bozik ME.

Laryngoscope. 2019 Feb;129(2):E61-E66. doi: 10.1002/lary.27564. Epub 2018 Oct 4.

PMID:
30284267
2.

Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes.

Panch SR, Bozik ME, Brown T, Makiya M, Prussin C, Archibald DG, Hebrank GT, Sullivan M, Sun X, Wetzler L, Ware J, Fay MP, Dunbar CE, Dworetzky SI, Khoury P, Maric I, Klion AD.

Blood. 2018 Aug 2;132(5):501-509. doi: 10.1182/blood-2018-02-835330. Epub 2018 May 8. Erratum in: Blood. 2018 Sep 27;132(13):1461.

3.

Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis.

Andrews JA, Meng L, Kulke SF, Rudnicki SA, Wolff AA, Bozik ME, Malik FI, Shefner JM.

JAMA Neurol. 2018 Jan 1;75(1):58-64. doi: 10.1001/jamaneurol.2017.3339.

4.

The targeted eosinophil-lowering effects of dexpramipexole in clinical studies.

Dworetzky SI, Hebrank GT, Archibald DG, Reynolds IJ, Farwell W, Bozik ME.

Blood Cells Mol Dis. 2017 Mar;63:62-65. doi: 10.1016/j.bcmd.2017.01.008. Epub 2017 Jan 16.

PMID:
28178599
5.

A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS.

Bozik ME, Mitsumoto H, Brooks BR, Rudnicki SA, Moore DH, Zhang B, Ludolph A, Cudkowicz ME, van den Berg LH, Mather J, Petzinger T Jr, Archibald D.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):406-13. doi: 10.3109/21678421.2014.943672. Epub 2014 Aug 15.

PMID:
25125035
6.

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.

Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA; EMPOWER investigators.

Lancet Neurol. 2013 Nov;12(11):1059-67. doi: 10.1016/S1474-4422(13)70221-7. Epub 2013 Sep 23. Erratum in: Lancet Neurol. 2013 Nov;12(11):1042. Carbonell, J G [corrected to Gamez, J].

PMID:
24067398
7.

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.

Cudkowicz M, Bozik ME, Ingersoll EW, Miller R, Mitsumoto H, Shefner J, Moore DH, Schoenfeld D, Mather JL, Archibald D, Sullivan M, Amburgey C, Moritz J, Gribkoff VK.

Nat Med. 2011 Nov 20;17(12):1652-6. doi: 10.1038/nm.2579.

PMID:
22101764
8.

Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects.

Bozik ME, Mather JL, Kramer WG, Gribkoff VK, Ingersoll EW.

J Clin Pharmacol. 2011 Aug;51(8):1177-85. doi: 10.1177/0091270010379412. Epub 2010 Oct 19.

PMID:
20959524
9.

KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis.

Gribkoff VK, Bozik ME.

CNS Neurosci Ther. 2008 Fall;14(3):215-26. doi: 10.1111/j.1755-5949.2008.00048.x. Review.

10.

Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo.

Okada H, Attanucci J, Giezeman-Smits KM, Brissette-Storkus C, Fellows WK, Gambotto A, Pollack LF, Pogue-Geile K, Lotze MT, Bozik ME, Chambers WH.

Cancer Res. 2001 Mar 15;61(6):2625-31.

11.

Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.

Giezeman-Smits KM, Okada H, Brissette-Storkus CS, Villa LA, Attanucci J, Lotze MT, Pollack IF, Bozik ME, Chambers WH.

Cancer Res. 2000 May 1;60(9):2449-57.

12.

Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy.

Okada H, Attanucci J, Tahara H, Pollack IF, Bozik ME, Chambers WH, Lotze MT.

Cancer Gene Ther. 2000 Mar;7(3):486-94.

13.

Survival of patients with high grade glioma treated with intrathecal thiotriethylenephosphoramide for ependymal or leptomeningeal gliomatosis.

Witham TF, Fukui MB, Meltzer CC, Burns R, Kondziolka D, Bozik ME.

Cancer. 1999 Oct 1;86(7):1347-53.

PMID:
10506724
14.

Brain tumor volume measurement: comparison of manual and semiautomated methods.

Joe BN, Fukui MB, Meltzer CC, Huang QS, Day RS, Greer PJ, Bozik ME.

Radiology. 1999 Sep;212(3):811-6.

PMID:
10478251
15.

Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine.

Okada H, Giezeman-Smits KM, Tahara H, Attanucci J, Fellows WK, Lotze MT, Chambers WH, Bozik ME.

Gene Ther. 1999 Feb;6(2):219-26.

16.

Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.

Chang SM, Kuhn JG, Robins HI, Schold SC, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Schiff D, Gilbert M, Rankin C, Prados MD.

J Clin Oncol. 1999 Mar;17(3):984-90.

PMID:
10071293
17.

Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms.

Okada H, Tahara H, Shurin MR, Attanucci J, Giezeman-Smits KM, Fellows WK, Lotze MT, Chambers WH, Bozik ME.

Int J Cancer. 1998 Oct 5;78(2):196-201.

18.

Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.

Chang SM, Kuhn JG, Rizzo J, Robins HI, Schold SC Jr, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Gilbert M, Fulton D, Rankin C, Malec M, Prados MD.

J Clin Oncol. 1998 Jun;16(6):2188-94.

PMID:
9626220
19.

Proliferation index as a predictor of prognosis in malignant gliomas of childhood.

Pollack IF, Campbell JW, Hamilton RL, Martinez AJ, Bozik ME.

Cancer. 1997 Feb 15;79(4):849-56.

PMID:
9024724
20.

The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood.

Pollack IF, Hamilton RL, Finkelstein SD, Campbell JW, Martinez AJ, Sherwin RN, Bozik ME, Gollin SM.

Cancer Res. 1997 Jan 15;57(2):304-9.

21.

NKR-P1+ cells localize selectively in Rat 9L gliosarcomas but have reduced cytolytic function.

Chambers WH, Bozik ME, Brissette-Storkus SC, Basse P, Redgate E, Watkins S, Boggs SS.

Cancer Res. 1996 Aug 1;56(15):3516-25.

Supplemental Content

Loading ...
Support Center